Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

The study compares time to next treatment or death for transplant-ineligible multiple myeloma patients treated with either DRd (daratumumab, lenalidomide, dexamethasone) or VRd (bortezomib, lenalidomide, dexamethasone). Results show that patients on DRd had a significantly longer median time to next treatment or death (37.8 months) than those on VRd (18.7 months), suggesting DRd's greater effectiveness in extending treatment duration in this population.